Castle BiosciencesCSTL
CSTL
About: Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Employees: 710
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
844% more call options, than puts
Call options by funds: $8.7M | Put options by funds: $921K
153% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 17
52% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 48
33% more capital invested
Capital invested by funds: $553M [Q2] → $734M (+$181M) [Q3]
16% more funds holding
Funds holding: 158 [Q2] → 184 (+26) [Q3]
0.74% more ownership
Funds ownership: 92.1% [Q2] → 92.84% (+0.74%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$36
31%
upside
Avg. target
$40
46%
upside
High target
$44
60%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Sung Ji Nam 50% 1-year accuracy 10 / 20 met price target | 60%upside $44 | Sector Outperform Maintained | 6 Nov 2024 |
Lake Street Thomas Flaten 33% 1-year accuracy 3 / 9 met price target | 45%upside $40 | Buy Maintained | 5 Nov 2024 |
Keybanc Paul Knight 25% 1-year accuracy 2 / 8 met price target | 31%upside $36 | Overweight Maintained | 5 Nov 2024 |
Baird Catherine Ramsey 83% 1-year accuracy 10 / 12 met price target | 42%upside $39 | Outperform Maintained | 5 Nov 2024 |
Canaccord Genuity Kyle Mikson 46% 1-year accuracy 12 / 26 met price target | 53%upside $42 | Buy Maintained | 29 Oct 2024 |
Financial journalist opinion
Based on 5 articles about CSTL published over the past 30 days
Neutral
Business Wire
2 days ago
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's Compensation Committee of its Board of Directors granted restricted stock units (RSUs) as inducement material to new employees.
Positive
Zacks Investment Research
4 days ago
4 Solid Net Profit Margin Stocks to Boost Portfolio Returns
Here, we present four stocks, CSTL, QFIN, ESEA and STRA, with solid net profit margins that can contribute toward making a strong portfolio.
Positive
Zacks Investment Research
5 days ago
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 42% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Business Wire
1 week ago
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Meta-analysis concludes DecisionDx-Melanoma provides improved risk stratification over staging alone to inform personalized management of melanoma.
Positive
Zacks Investment Research
3 weeks ago
Small Caps Are Winners of 2024: 5 Picks With Solid Short-Term Upside
These five small cap stocks have strong growth potential for 2025. These are: TALK, RYAM, CSTL, PBAM, RSSS.
Neutral
Business Wire
1 month ago
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's executive management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Dec. 4, 2024, at 10:50 am ET.
Neutral
Business Wire
1 month ago
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle has been named a Houston Top Workplace by the Houston Chronicle for the 4th straight year and has earned 3 national Culture Excellence awards.
Positive
Zacks Investment Research
1 month ago
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Castle Biosciences (CSTL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Neutral
Business Wire
1 month ago
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP24--Castle will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the ASDP 61st Annual Meeting.
Positive
Zacks Investment Research
1 month ago
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Charts implemented using Lightweight Charts™